tiprankstipranks
Trending News
More News >
TuHURA Biosciences (HURA)
NASDAQ:HURA

TuHURA Biosciences (HURA) AI Stock Analysis

Compare
925 Followers

Top Page

HU

TuHURA Biosciences

(NASDAQ:HURA)

Rating:36Underperform
Price Target:
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company's poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
Positive Factors
Clinical Trials & Approvals
The initiation of the Phase 3 accelerated approval trial of IFx-2.0 in patients with advanced or metastatic Merkel cell carcinoma is a significant step forward for Tuhura Biosciences.
Financial Performance
Tuhura Biosciences announced it entered into an equity financing that should bring in an aggregate $12.5M in capital, providing financial runway into the first half of 2026.
Mergers & Acquisitions
The merger with Kineta Inc has been approved by stockholders, promising to bring Kineta's anti-VISTA antibody into Tuhura's portfolio, potentially enhancing their research capabilities.
Negative Factors
Clinical Risks
Risks include negative clinical results with IFx-2.0 and delays in advancing pipeline candidates into registrational programs.
Competitive Risks
There are competitive risks, especially with respect to other checkpoint inhibitors, which could impact Tuhura Biosciences' market position.

TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)

TuHURA Biosciences Business Overview & Revenue Model

Company DescriptionTuHURA Biosciences (HURA) is a biotechnology company focused on the development and commercialization of innovative therapeutics and diagnostics in the field of personalized medicine. The company operates primarily in the pharmaceutical and healthcare sectors, leveraging cutting-edge genomic technologies to create targeted treatment solutions. Its core products include proprietary diagnostic tests and personalized therapeutic interventions aimed at improving patient outcomes across various disease areas.
How the Company Makes MoneyTuHURA Biosciences generates revenue through multiple streams, primarily from the sale of its diagnostic tests and personalized therapeutic products. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to integrate its solutions into clinical settings, driving adoption and sales. Additionally, TuHURA may enter into licensing agreements and strategic partnerships to commercialize its technologies, expanding its market reach and generating royalties. Grants and funding from research initiatives may also contribute to the company's earnings, supporting its ongoing research and development efforts.

TuHURA Biosciences Financial Statement Overview

Summary
TuHURA Biosciences is facing severe financial challenges, with no revenue generation and increasing net losses. The balance sheet reflects significant financial instability, and cash flow statements indicate ongoing cash burn problems. The company appears to be heavily reliant on external financing to maintain operations, posing substantial risks to its long-term viability.
Income Statement
10
Very Negative
TuHURA Biosciences has consistently reported zero revenue, indicating challenges in commercializing its products or services. The company faces increasing net losses, with a substantial net profit margin decline. The negative EBIT and EBITDA margins highlight ongoing operational inefficiencies.
Balance Sheet
15
Very Negative
The balance sheet reveals a troubling negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, but high liabilities relative to assets suggest significant leverage. The equity ratio is negative, further emphasizing financial distress.
Cash Flow
20
Very Negative
Cash flow analysis shows negative operating and free cash flows over time, highlighting cash burn issues. The company is not generating sufficient cash from operations to sustain itself, relying heavily on financing activities for liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Jun 2021
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit-116.71K0.000.000.00-32.00K
EBITDA-17.43M-29.12M-9.56M-6.01M-38.15M
Net Income-21.68M-29.32M-9.37M-7.02M-38.30M
Balance Sheet
Total Assets19.97M4.36M15.20M6.40M13.54M
Cash, Cash Equivalents and Short-Term Investments12.66M3.67M14.25M5.55M10.54M
Total Debt202.54K2.34M138.22K644.07K0.00
Total Liabilities5.37M5.92M2.89M7.15M2.96M
Stockholders Equity14.59M-1.56M12.30M-747.82K10.58M
Cash Flow
Free Cash Flow-14.79M-12.03M-7.54M-6.57M-18.87M
Operating Cash Flow-14.73M-11.95M-7.51M-6.56M-18.86M
Investing Cash Flow-6.05M-1.30M-36.28K-3.28K964.00K
Financing Cash Flow29.77M2.66M16.25M7.04M26.04M

TuHURA Biosciences Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.61
Price Trends
50DMA
3.22
Negative
100DMA
3.26
Negative
200DMA
4.26
Negative
Market Momentum
MACD
-0.23
Negative
RSI
46.84
Neutral
STOCH
53.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Neutral. The current price of 2.61 is above the 20-day moving average (MA) of 2.55, below the 50-day MA of 3.22, and below the 200-day MA of 4.26, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 46.84 is Neutral, neither overbought nor oversold. The STOCH value of 53.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HURA.

TuHURA Biosciences Risk Analysis

TuHURA Biosciences disclosed 72 risk factors in its most recent earnings report. TuHURA Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

TuHURA Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$321.09M-86.09%1250.63%37.24%
PLPLX
56
Neutral
$119.41M35.7110.42%0.18%-55.15%
51
Neutral
$269.40M-198.47%-38.74%
49
Neutral
AU$2.47B4.40-64.25%2.83%36.51%13.14%
45
Neutral
$372.06M-32.12%10.98%
36
Underperform
$121.49M-244.16%77.12%
35
Underperform
$284.13M-500.57%81.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HURA
TuHURA Biosciences
2.61
-7.89
-75.14%
LXRX
Lexicon Pharmaceuticals
0.92
-0.75
-44.91%
PLX
Protalix
1.50
0.45
42.86%
DBVT
DBV Technologies SA - American
10.30
6.11
145.82%
GOSS
Gossamer Bio
1.21
0.13
12.04%
TERN
Terns Pharmaceuticals
4.26
-2.55
-37.44%

TuHURA Biosciences Corporate Events

M&A Transactions
TuHURA Biosciences Announces Acquisition of Kineta, Inc.
Neutral
Mar 18, 2025

On March 18, 2025, TuHURA Biosciences announced its intention to acquire Kineta, Inc., which will enhance its product pipeline with Kineta’s VISTA-101 development program. The merger is expected to bring significant synergies and strengthen TuHURA’s position in the biopharmaceutical sector, although it involves various risks and uncertainties related to regulatory approvals and market conditions.

Executive/Board ChangesBusiness Operations and Strategy
TuHURA Biosciences Expands Board with New Appointment
Positive
Mar 12, 2025

On March 10, 2025, TuHURA Biosciences appointed Dr. Craig Tendler to its Board of Directors, expanding the board to six members. Dr. Tendler brings extensive experience from his previous role at Johnson & Johnson, where he oversaw major drug approvals and FDA breakthrough designations in oncology. His expertise is expected to aid TuHURA in advancing its drug development programs and evaluating potential collaborations and acquisitions, particularly as the company prepares for a Phase 3 trial of its drug candidate IFx-2.0.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025